Fig. 3.

Relative decrease in overall HCV incidence over 2018 to 2030 due to different HCV screening and treatment scenarios among MSM on PrEP and/or HIV-diagnosed MSM. MSM subgroups with enhanced screening also complete HCV treatment within 6 months of diagnosis. Projections are given (A) without and (B) with risk compensation, with the risk compensation scenario assuming condom use among PrEP users reduces from 68% to 34%. Dashed line in each figure gives change in HCV incidence by 2030 with no change in HCV screening. Point estimates are the median of our model projections with whiskers representing the 2·5 to 97·5 percentile range from our 500 model fits.